Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Friday's session: top gainers and losers in the S&P500 index

2026-05-29
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

ResMed Inc (NYSE:RMD): A Top Dividend Stock with Strong Profitability and Financial Health

2026-05-28
ResMed (RMD) offers a safe, growing dividend backed by strong profitability and financial health. With a 7/10 dividend rating, 22% payout ratio, and top-tier earnings quality, it exemplifies a sustainable income strategy.

Do Wall Street Analysts Like ResMed Stock?

2026-05-25
ResMed continues to command steady Wall Street confidence despite recent stock pressure and a few bumps along the road.

2 Healthcare Stocks to Research Further and 1 We Find Risky

2026-05-23
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.8% return has trailed the S&P 500 by 9 percentage points.

3 Large-Cap Stocks to Consider Right Now

2026-05-22
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

How Investors Are Reacting To ResMed (RMD) Linking Oura Ring Wearables To Clinical Sleep Care

2026-05-20
ResMed recently announced a collaboration with ŌURA that connects Oura Ring members in the U.S. to ResMed’s sleep education tools, assessments, and options to engage independent healthcare providers for potential conditions such as obstructive sleep apnea. This partnership links consumer wearables with clinical sleep pathways, potentially widening the funnel from at-home tracking to medically supervised diagnosis and treatment. We’ll now examine how integrating ŌURA’s wearable sleep insights...

Is the Options Market Predicting a Spike in ResMed Stock?

2026-05-20
Investors need to pay close attention to RMD stock based on the movements in the options market lately.

ResMed (RMD) Valuation Check As Oura Sleep Health Collaboration Aims To Expand Sleep Apnea Care Access

2026-05-20
ResMed (RMD) is in focus after announcing a collaboration with Oura that connects Oura Ring users in the US to ResMed’s sleep education tools, assessments, and potential care pathways for obstructive sleep apnea. See our latest analysis for ResMed. The collaboration with Oura lands at a time when momentum in ResMed’s share price has cooled, with the stock down about 19.8% on a 90-day share price return and its 1-year total shareholder return down around 15.5%, even after a recent 1-week share...

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

2026-05-19
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed’s webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://inv

Silver Economy Investing: Why the Healthcare Giants Are in Focus

2026-05-19
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.